Source link : https://www.newshealth.biz/health-news/amyloidosis-drug-improves-outcomes-survival/
LONDON — Vutrisiran (Amvuttra) improved functional and disease outcomes as well as survival in transthyretin amyloidosis cardiomyopathy (ATTR-CM), according to findings from the HELIOS-B phase III trial. And the benefits in comparison with placebo were seen regardless of background use of TTR stabilizer tafamidis (Vyndamax, Vyndaqel), as Marianna Fontana, MD, PhD, of University College London, […]
Author : News Health
Publish date : 2024-08-30 16:36:51
Copyright for syndicated content belongs to the linked Source.